Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline demographics, treatment and levels of serological biomarkers

From: Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study

  Included patients n = 163 Excluded patients n = 75 P value
Demographic variables    
Female 75.0 70.5 0.53
Age (years) 53.0 (43.0 to 62.3) 57.0 (43.5 to 64.5) 0.23
Disease duration (years) 2.4 (1.2 to 3.2) 2.5 (1.2 to 3.1) 0.95
HAQ 0.9 (0.4 to 1.4) 1.0 (0.4 to 1.4) 0.60
Treatment    
DMARD use 53.8 48.7 0.49
Prednisolone use 26.3 29.5 0.64
Serological biomarkers    
ESR (mm/h) 20.0 (10.0 to 38.0) 24.0 (10.5 to 35.5) 0.65
ESR > 20 mm/h 48.5 52.0 0.58
CRP (mg/l) 6.0 (0.0 to 15.0) 7.0 (2.5 to 14.5) 0.36
CRP > 10 mg/l 28.8 26.0 0.66
IgA RF (U/ml) 13.0 (4.0 to 41.3) 17.5 (1.8 to 75.0) 0.56
IgA RF positive 30.2 33.3 0.87
IgM RF (U/ml) 21.0 (5.0 to 105.0) 26.5 (2.0 to 131.0) 0.66
IgM RF positive 41.7 66.7 0.40
Anti-CCP (U/ml) 67.0 (4.4 to 243.0) 56.0 (3.5 to 251.0) 0.82
Anti-CCP positive 60.4 66.7 0.76
  1. The values are given as median (inter quartile range) for continuous variables, percentage for counts.
  2. Anti-CCP = antibodies to cyclic citrullinated peptide; CRP = C-reactive protein; DMARD = disease-modifying antirheumatic drugs; ESR = erythrocyte sedimentation rate; HAQ = health assessment questionnaire; Ig = immunoglobulin; RF = rheumatoid arthritis.